Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 5/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.40 |
| ▸ | THRA | P10827 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | TAS1R3 | Q7RTX0 | 6/20 | 0.39 |
| ▸ | TAS1R1 | Q7RTX1 | 6/20 | 0.39 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.35 |
| ▸ | WNT3A | P56704 | 1/20 | 0.35 |
| ▸ | GNG2 | P59768 | 1/20 | 0.35 |
| ▸ | GNB1 | P62873 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6812398 | 0.87 | MEN1 (0.43) | THRATHRBTAS1R3TAS1R1 | |
| SCHEMBL6811142 | 0.84 | THRA (0.49) | THRATHRBTAS1R3TAS1R1CTNNB1 | |
| SCHEMBL5461932 | 0.82 | ALDH1A1 (0.41) | TAS1R3TAS1R1 | |
| SCHEMBL5595633 | 0.81 | ALDH1A1 (0.40) | THRATHRBTAS1R3TAS1R1 | |
| SCHEMBL6808442 | 0.80 | TAS1R3 (0.41) | THRATHRBTAS1R3TAS1R1 | |
| SCHEMBL2462140 | 0.79 | GSK3B (0.56) | GSK3BPTPN1TAS1R3TAS1R1CTNNB1 | |
| SCHEMBL2099644 | 0.77 | GSK3B (0.59) | GSK3BPTPN1 | |
| SCHEMBL9589309 | 0.77 | PDE4D (0.47) | GSK3BPTPN1 | |
| SCHEMBL6808409 | 0.76 | MEN1 (0.41) | — | |
| SCHEMBL5466966 | 0.75 | HPGDS (0.31) | THRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070021414-A1 | 1-'2-(4-Hydroxyphenyl)-2-hydroxyethyl!-piperidin-4-ol compounds as nmda receptor antagonists | PFIZER, INC. | 2007-01-25 | — | — | US | disclosed |
| EP-1673366-A1 | 1-\"2-(4-HYDROXYPHENYL)-2-HYDROXYETHYL]-PIPERIDIN-4-OL COMPOUNDS AS NMDA RECEPTOR ANTAGONISTS | Pfizer, Inc. (US) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005035522-A1 | 1-‘2-(4-HYDROXYPHENYL)-2-HYDROXYETHYL!-PIPERIDIN-4-OL COMPOUNDS AS NMDA RECEPTOR ANTAGONISTS | PFIZER JAPAN, INC. (JP) | 2005-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021414-A1 | 1-'2-(4-Hydroxyphenyl)-2-hydroxyethyl!-piperidin-4-ol compounds as nmda receptor antagonists | GRIN1, GRIN3A, GRIN2C | GSK3B 3218/4885PTPN1 1602/4885THRA 925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.